Literature DB >> 17680563

Combination of human plasminogen kringle 5 with ionizing radiation significantly enhances the efficacy of antitumor effect.

Guang-Hui Jin1, Ding-Yuan Ma, Ning Wu, Faiz M M T Marikar, Shun-Zi Jin, Wei-Wei Jiang, Yan Liu, Zi-Chun Hua.   

Abstract

Antiangiogenic therapy could destroy tumor vasculature and inhibit tumor growth. It might inhibit tumor growth significantly when used as a single treatment modality and its therapeutic benefit may even be greater when used in combination with established treatment modalities such as radiation therapy (RT). In the present report, we investigated the effect of recombinant human plasminogen kringle 5 domain (rhK5) in combination with ionizing radiation on angiogenesis, tumor growth and survival in a murine Lewis lung carcinoma (LLC) tumor model. Combined treatment using rhK5 and radiotherapy displayed obvious suppressive effect on LLC tumor growth as compared with single treatment with either modality (p < 0.05), and resulted in a more additive effect on tumor growth delay in this model. In addition, combined treatment significantly enhanced the survival of mice and no toxic effect, such as weight loss, was observed. The significant antitumor effect of rhK5 plus radiation was associated with a direct suppression effect on early neoangiogenesis and tumor cell apoptosis. Furthermore, the expression of VEGF and HIF-1alpha in tumor tissue correlated well with decreased vessel density. The results suggest that rhK5 significantly enhances the antitumor activity of RT and could be a potent adjuvant therapeutic approach to improve the efficacy of radiotherapy for lung cancer. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17680563     DOI: 10.1002/ijc.22708

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Plasminogen kringle 5 induces apoptosis of brain microvessel endothelial cells: sensitization by radiation and requirement for GRP78 and LRP1.

Authors:  Braden C McFarland; Jerry Stewart; Amal Hamza; Robert Nordal; Donald J Davidson; Jack Henkin; Candece L Gladson
Journal:  Cancer Res       Date:  2009-06-23       Impact factor: 12.701

2.  Targeted antivascular therapy with the apolipoprotein(a) kringle V, rhLK8, inhibits the growth and metastasis of human prostate cancer in an orthotopic nude mouse model.

Authors:  Ho-Jeong Lee; Hyun-Kyung Yu; John N Papadopoulos; Seung Wook Kim; Junqin He; Yong-Keun Park; Yeup Yoon; Jang-Seong Kim; Sun Jin Kim
Journal:  Neoplasia       Date:  2012-04       Impact factor: 5.715

3.  Modification of cyclic NGR tumor neovasculature-homing motif sequence to human plasminogen kringle 5 improves inhibition of tumor growth.

Authors:  Weiwei Jiang; Guanghui Jin; Dingyuan Ma; Feng Wang; Tong Fu; Xiao Chen; Xiwen Chen; Kunzhi Jia; Faiz M M T Marikar; Zichun Hua
Journal:  PLoS One       Date:  2012-05-10       Impact factor: 3.240

4.  Lung cancer cell migration is regulated via repressing growth factor PTN/RPTP β/ζ signaling by menin.

Authors:  Z-J Feng; S-B Gao; Y Wu; X-F Xu; X Hua; G-H Jin
Journal:  Oncogene       Date:  2010-07-19       Impact factor: 9.867

5.  Dual inhibition of plasminogen kringle 5 on angiogenesis and chemotaxis suppresses tumor metastasis by targeting HIF-1α pathway.

Authors:  Wei-Bin Cai; Yang Zhang; Rui Cheng; Zheng Wang; Shu-Huan Fang; Zu-Min Xu; Xia Yang; Zhong-Han Yang; Jian-Xing Ma; Chun-Kui Shao; Guo-Quan Gao
Journal:  PLoS One       Date:  2012-12-31       Impact factor: 3.240

6.  Baculovirus vector-mediated transfer of sodium iodide symporter and plasminogen kringle 5 genes for tumor radioiodide therapy.

Authors:  Min Zhang; Rui Guo; Shuo Shi; Yin Miao; Yifan Zhang; Biao Li
Journal:  PLoS One       Date:  2014-03-19       Impact factor: 3.240

7.  Suppression of colorectal cancer liver metastasis by apolipoprotein(a) kringle V in a nude mouse model through the induction of apoptosis in tumor-associated endothelial cells.

Authors:  Jin-Hyung Ahn; Hyun-Kyung Yu; Ho-Jeong Lee; Soon Won Hong; Sun Jin Kim; Jang-Seong Kim
Journal:  PLoS One       Date:  2014-04-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.